Know Cancer

forgot password

Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study

Phase 2
18 Years
Not Enrolling
Breast Cancer, HER2 Positive

Thank you

Trial Information

Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study

Inclusion Criteria:

- Histologically or cytologically confirmed infiltrating breast cancer.

- Stage II or stage III breast cancer.28 'Locally advanced breast cancer' patients are
consequently eligible, including those with ipsilateral supraclavicular lymph node
metastases. N1 status must have been demonstrated by either fine needle aspiration
from an axillary lymph node or by a metastasis of >2 mm in diameter at sentinel node
biopsy. Stage IIA patients are eligible if the tumor is >3 cm in diameter or if the
tumor is between 2 and 3 cm in diameter but a breast conserving surgery is not

- Overexpression and/or amplification of HER2 in an invasive component of the core
biopsy, according to one of the following definitions:

- >10% of invasive tumor cells showing strong complete circumferential membrane
staining (score 3+)

- >10% of invasive tumor cells showing moderate complete circumferential membrane
staining (score 2+) and demonstrating HER2 gene amplification defined as a FISH
ratio of HER2 gene copies to chromosome 17 signals of >2.2. or as >5 HER2 gene
copies per nucleus in CISH analysis.

Patients with a negative or equivocal overall result (FISH test ratio of <2.2, <6.0 HER2
gene copies per nucleus) and staining scores of 0,1+, 2+ or 3+ (in 30% or less neoplastic
cells) by IHC are not eligible for participation in the trial.

- Age ≥18

- Eastern Cooperative Oncology Group (ECOG) performance status ≤1 (Appendix B)

- Adequate bone marrow function (ANC >1.0 x 109/l, platelets >100 x 109/l)

- Adequate hepatic function (ALAT, ASAT and bilirubin <2 times upper limit of normal)

- Adequate renal function (creatinine clearance >60 ml/min)

- LVEF ≥50% measured by echocardiography or MUGA

- Absence of any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule

- Signed written informed consent

Exclusion Criteria:

- No previous radiation therapy or chemotherapy

- No other malignancy except carcinoma in situ, unless the other malignancy was treated
≥5 years ago with curative intent without the use of chemotherapy or radiation

- No current pregnancy or breastfeeding. Women of childbearing potential must use
adequate contraceptive protection.

- No evidence of distant metastases. Staging examinations must have included a chest
radiograph, an ultrasound examination of the liver and an isotope bone scan. Abnormal
uptake on the isotope bone scan can only be accepted if MRI, CT-scan, or plain
radiograph excludes bone metastases.

- No concurrent anti-cancer treatment or another investigational drug

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Pathologic complete response (pCR) rate at surgery

Outcome Time Frame:

at the completion of neo-adjuvant chemotherapy

Safety Issue:


Principal Investigator

G S Sonke, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:



Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Study ID:




Start Date:

September 2008

Completion Date:

May 2012

Related Keywords:

  • Breast Cancer
  • HER2 Positive
  • breast cancer
  • HER2 positive
  • neo-adjuvant
  • trastuzumab
  • paclitaxel
  • carboplatin
  • Breast Neoplasms